Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

2020364 citationsJournal Articlehybrid Open Access

Authors

D. Ross Camidge · University of Colorado Cancer Center

Hye Ryun Kim · Yonsei University

Myung‐Ju Ahn · Samsung Medical Center

James Chih‐Hsin Yang · National Taiwan University Hospital

Ji‐Youn Han · National Cancer Center

Maximilian J. Hochmair

Ki Hyeong Lee · Chungbuk National University Hospital

Abstract

Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lymphoma Diagnosis and Treatment

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 31, pp. 3592-3603

DOI: 10.1200/jco.20.00505

Field-Weighted Citation Impact: 34.22

Command Palette

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Authors

Abstract

Topics & Keywords

Publication Details